Lung damage and airway remodelling in severe asthma

Clinical and Experimental Allergy

Volumn 42, Issue 5, 2012, Pages 638-649

  Brightling, C E ^a   Gupta, S ^b   Gonem, S ^b   Siddiqui, S ^b  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b GLENFIELD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AIRWAY REMODELING; ASTHMA; DISEASE ACTIVITY; DISEASE SEVERITY; GENETIC ASSOCIATION; HUMAN; LUNG INJURY; PATHOGENESIS; PERSONALIZED MEDICINE; PHENOTYPE; PNEUMONIA; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION;

AIRWAY REMODELING; ASTHMA; HUMANS; INFLAMMATION; LUNG; MODELS, BIOLOGICAL; PHENOTYPE; SEVERITY OF ILLNESS INDEX;

EID: 84859983419     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2011.03917.x     Document Type: Review

References (141)

1. Bousquet J, Mantzouranis E, Cruz AA et al. Uniform definition of asthma severity, control, and exacerbation: document presented for the World Health Organisation Consultation on Severe Asthma. J Allergy Clin Immunol 2010; 126:926-38.
2. American Thoracic Society. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. Am J Respir Crit Care Med 2000; 162:2341-51.
3. Chung KF, Godard P, Adelroth E et al.Difficult/therapy-resistant asthma: the need for an integrated approach to define clinical phenotypes, evaluate risk factors, understand pathophysiology and find novel therapies. ERS Task Force on Difficult/Therapy-Resistant Asthma. European Respiratory Society. Eur Respir J 1999; 13:1198-208.
4. Taylor DR, Bateman ED, Boulet LP et al.A new perspective on concepts of asthma severity and control. Eur Respir J 2008; 32:545-54.
5. Chanez P, Wenzel SE, Anderson GP et al. Severe asthma in adults: what are the important questions? J Allergy Clin Immunol 2007; 119:1337-48.
6. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention, 2006, (2008 update). Available at: (accessed 15 October 2011).
7. Holgate ST, Roberts G, Arshad HS, Howarth PH, Davies DE. The role of the airway epithelium and its interaction with environmental factors in asthma pathogenesis. Proc Am Thorac Soc. 2009; 6:655-9.
8. Lange P, Parner J, Vestbo J, Schnohr P, Jensen G. A 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med 1998; 339:1194-200.
9. Contoli M, Baraldo S, Marku B et al. Fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease: a 5-year follow-up. J Allergy Clin Immunol 2010; 125:830-7.
10. Gupta S, Raj V, Castro M, Brightling CE, Gupta ERS monograph. Imaging in severe asthma. Eur Respir Monograph 2011; 51:160-81.
11. Gupta S, Siddiqui S, Haldar P et al. Qualitative analysis of high-resolution CT scans in severe asthma. Chest 2009; 136:1521-8.
12. Paganin F, Seneterre E, Chanez P et al. Computed tomography of the lungs in asthma: influence of disease severity and etiology. Am J Respir Crit Care Med 1996; 153:110-4.
13. Yilmaz S, Ekici A, Ekici M et al. High-resolution computed tomography findings in elderly patients with asthma. Eur J Radiol 2006; 59:238-43.
14. Lynch DA, Newell JD, Tschomper BA et al. Uncomplicated asthma in adults: comparison of CT appearance of the lungs in asthmatic and healthy subjects. Radiology 1993; 188:829-33.
15. Bumbacea D, Campbell D, Nguyen L et al. Parameters associated with persistent airflow obstruction in chronic severe asthma. Eur Respir J 2004; 24:122-8.
16. Takemura M, Niimi A, Minakuchi M et al. Bronchial dilatation in asthma: relation to clinical and sputum indices. Chest 2004; 125:1352-8.
17. Gupta S, Siddiqui S, Haldar P et al. Quantitative analysis of high-resolution computed tomography scans in severe asthma subphenotypes. Thorax 2010; 65:775-81.
18. Aysola RS, Hoffman EA, Gierada D et al. Airway remodeling measured by multidetector CT is increased in severe asthma and correlates with pathology. Chest 2008; 134:1183-91.
19. Siddiqui S, Gupta S, Cruse G et al. Airway wall geometry in asthma and nonasthmatic eosinophilic bronchitis. Allergy 2009; 64:951-8.
20. Wild JM, Woodhouse N, Teh K. Single-scan acquisition of registered hyperpolarized (3)He ventilation and ADC images using a hybrid 2D gradient-echo sequence. Magn Reson Med 2007; 57:1185-9.
21. van BE, Dahmen AM, Stavngaard T et al. Hyperpolarised 3He MRI versus HRCT in COPD and normal volunteers: PHIL trial. Eur Respir J 2009; 34:1311-21.
22. Busacker A, Newell JD Jr, Keefe T et al. A multivariate analysis of risk factors for the air-trapping asthmatic phenotype as measured by quantitative CT analysis. Chest 2009; 135:48-56.
23. Prad AS, Lutchen KR. Respiratory impedance measurements for assessment of lung mechanics: focus on asthma. Respir Physiol Neurobiol 2008; 163:64-73.
24. Gustafsson PM, Ljungberg HK, Kjellman B. Peripheral airway involvement in asthma assessed by single-breath SF6 and He washout. Eur Respir J 2003; 21:1033-9.
25. Campana L, Kenyon J, Zhalehdoust-Sani S et al. Probing airway conditions governing ventilation defects in asthma via hyperpolarised MRI inmage functional modeling. J Appl Physiol 2009; 106:1293-300.
26. Gonem S, Ball I, Corkill S et al. Localisation of the site of fixed airflow obstruction in moderate to severe asthma using hyperpolarised helium-3 magnetic resonance imaging. British Thoracic Society Winter Meeting 2011 (abstract).
27. Gonem S, Ball I, Corkill S et al. Repeatability and inter-relationships of small airway biomarkers. British Thoracic Society Winter Meeting 2011 (abstract).
28. Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ. HMGB1 and RAGE in inflammation and cancer. Ann Rev Immunol 2010; 28:367-88.
29. Zhang L, Bukulin M, Kojro E et al. Receptor for advanced gylcation end products is subjected to protein ectodomain shedding by metalloproteinases. J Biol Chem 2008; 283:35507-16.
30. Repapi E, Sayers I, Wain LV et al. Genome-wide association study identifies five loci associated with lung function. Nat Genet 2010; 42:36-44.
31. Hancock DB, Eijgelsheim M, Wilk JB et al. Meta-analysis of genome-wide association studies identify multiple loci associated with pulmonary function. Nat Genet 2010; 42:45-52.
32. Ferhani N, Letuve S, Kozhich A et al. Expression of high-mobility group box 1 and the receptor for advanced glycation end products in COPD. Am J Respir Crit Care Med 2010; 181:917-27.
33. Wu L, Ma L, Nicholson LFB, Black PN. Advanced glycation end products and its receptor (RAGE) are increased in patients with COPD. Respir Med 2011; 105:329-36.
34. Sukkar MB, Wood LG, Tooze M et al. Soluble RAGE is deficient in neutrophilic asthma and chronic obstructive pulmonary disease. Eur Respir J 2011, in press.
35. Hilty M, Burke C, Pedro H et al. Disordered microbial communities in asthmatic airways. PLoS ONE 2010; 5:e8578.
36. Huang YJ, Nelson CE, Brodie EL et al. National Heart, Lung, and Blood Institute's Asthma Clinical Research Network. Airway microbiota and bronchial hyperresponsiveness in patients with suboptimally controlled asthma. J Allergy Clin Immunol 2011; 127:372-81.e1-3.
37. Fairs A, Agbetile J, Hargadon B et al. IgE sensitization to Aspergillus fumigates is associated with reduced lung function in asthma. Am J Respir Crit Care Med 2010; 182:1362-8.
38. Ten Brinke A, van Dissel JT, Sterk PJ, Zwinderman AH, Rabe KF, Bel EH. Persistent airflow limitation in adult onset nonatopic asthma is associated with serologic evidence of Chlamydia pneumonia infection. J Allergy Clin Immunol 2001; 107:449-54.
39. Thomas B, Rutman A, Hirst RA et al. Ciliary dysfunction and ultrastructural abnormalities are features of severe asthma. J Allergy Clin Immunol 2010; 126:722-9.
40. Wark PA, Johnston SL, Bucchieri F et al. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J Exp Med 2005; 201:937-47.
41. Contoli M, Message SD, Laza-Stanca V et al. Role of deficient type III interferon-lambda production in asthma exacerbations. Nat Med 2006; 12:1023-6.
42. Little SA, MacLeod KJ, Chalmers GW, Love JG, McSharry C, Thomson NC. Association of forced expiratory volume with disease duration and sputum neutrophils in chronic asthma. Am J Med 2002; 112:446-52.
43. Chaudhuri R, Livingston E, McMahon AD, Thomson L, Borland W, Thomson NC. Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma. Am J Respir Crit Care Med 2003; 168:1308-11.
44. Slats AM, Janssen K, van Schadewijk A et al. Bronchial inflammtion and airway responses to deep inspiration in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 176:121-8.
45. Grainge CL, Lau LC, Ward JA et al. Effect of bronchoconstriction on airway remodelling in asthma. N Engl J Med 2011; 364:2006-15.
46. Berry MA, Parker D, Neale N et al. Sputum and bronchial submucosal IL-13 expression in asthma and eosinophilic bronchitis. J Allergy Clin Immunol 2004; 114:1106-9.
47. Brightling CE, Symon FA, Birring SS et al. TH2 cytokine expression in bronchoalveolar lavage fluid T lymphocytes and bronchial submucosa is a feature of asthma and eosinophilic bronchitis. J Allergy Clin Immunol 2002; 110:899-905.
48. Saha SK, Berry MA, Parker D et al. Increased sputum and bronchial biopsy IL-13 expression in severe asthma. J Allergy Clin Immunol 2008; 121:685-91.
49. Semlali A, Jacques E, Koussih L et al. Thymic stromal lymphopoietin-induced human asthmatic airway epithelial cell proliferation through an IL-13-dependent pathway. J Allergy Clin Immunol 2010; 125:844-50.
50. Okayama Y, Okumura S, Sagara H et al. FcepsilonRI-mediated thymic stromal lymphopoietin production by interleukin-4-primed human mast cells. Eur Respir J 2009; 34:425-35.
51. Zhang K, Shan L, Rahman MS et al. Constitutive and inducible thymic stromal lymphopoietin expression in human airway smooth muscle cells: role in chronic obstructive pulmonary disease. Am J Physiol Lung Cell Mol Physiol 2007; 293:L375-82.
52. Kashyap M, Rochman Y, Spolski R et al. Thymic stromal lymphopoietin is produced by dendritic cells. J Immunol 2011. [Epub ahead of print].
53. Ying S, O'Connor B, Ratoff J et al. Expression and cellular provenance of thymic stromal lymphopoietin and chemokines in patients with severe asthma and chronic obstructive pulmonary disease. J Immunol 2008; 181:2790-8.
54. Kaur D, Doe C, Woodman L et al. Mast cell-airway smooth muscle crosstalk promotes mast cell activation via thymic stromal lymphopoietin. Chest 2011, in press.
55. Siddiqui S, Mistry V, Doe C, Stinson S, Foster M, Brightling C. Airway wall expression of OX40/OX40L and interleukin-4 in asthma. Chest 2010; 137:797-804.
56. Green RH, Brightling CE, Woltmann G, Parker D, Wardlaw AJ, Pavord ID. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 2002; 57:875-9.
57. Wenzel SE, Schwartz LB, Langmack EL et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999; 160:1001-8.
58. Brightling CE. Clinical applications of induced sputum. Chest 2006; 129:1344-8.
59. Barnes PJ The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest 2008; 118:3546-56.
60. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma. Eur Respir J. 2003; 22:470-7.
61. Haldar P, Pavord ID, Shaw DE et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008; 178:218-24.
62. Doe C, Bafadhel M, Siddiqui S et al. Brightling expression of the Th17-associated cytokines interleukin (IL)-17A and F in asthma and chronic obstructive pulmonary disease. Chest 2010; 138:1140-7.
63. Al-Ramli W, Préfontaine D, Chouiali F et al. T(H)17-associated cytokines (IL-17A and IL-17F) in severe asthma. J Allergy Clin Immunol 2009; 123:1185-7.
64. Haldar P, Brightling CE, Hargadon B et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360:973-84.
65. Ten Brinke A, Sterk PJ, Masclee AA et al. Risk factors of frequent exacerbations in difficult-to-treat asthma. Eur Respir J 2005; 26:812-8.
66. Woodruff PG, Khashayar R, Lazarus SC et al. Relationship between airway inflammation, hyperresponsiveness, and obstruction in asthma. J Allergy Clin Immunol 2001; 108:753-8.
67. Shaw DE, Berry MA, Hargadon B et al. Association between neutrophilic airway inflammation and airflow limitation in adults with asthma. Chest 2007; 132:1871-5.
68. Howarth P, Babu K, Arshad H et al. Tumournecrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroiddependent asthma. Thorax 2005; 60:1012-8.
69. Balzar S, Fajt ML, Comhair SA et al. Mast cell phenotype, location, and activation in severe asthma. Data from the severe asthma research program. Am J Respir Crit Care Med 2011; 183:299-309.
70. Balzar S, Chu HW, Strand M, Wenzel S Relationship of small airway chymase-positive mast cells and lung function in severe asthma. Am J Respir Crit Care Med 2005; 171:431-9.
71. Puddicombe SM, Polosa R, Richter A et al. Involvement of the epidermal growth factor receptor in epithelial repair in asthma. FASEB J 2000; 14:1362-74.
72. Duvernelle C, Freund V, Frossard N. Transforming growth factor-beta and its role in asthma. Pulm Pharmacol Ther 2003; 16:181-96.
73. Chetta A, Zanini A, Foresi A et al. Vascular endothelial growth factor up-regulation and bronchial wall remodelling in asthma. Clin Exp Allergy 2005; 35:1437-42.
74. Eickelberg O, Kohler E, Reichenberger F et al. Extracellular matrix deposition by primary human lung fibroblasts in response to TGF-beta1 and TGF-beta3. Am J Physiol 1999; 276:L814-24.
75. Cohen L, Tarsi EX, Ramkumar J et al.; the NHLBI Severe Asthma Research Program (SARP). Epithelial cell proliferation contributes to airway remodeling in severe asthma. Am J Respir Crit Care Med 2007; 176:138-45.
76. Shannon J, Ernst P, Yamauchi Y et al. Differences in airway cytokine profile in severe asthma compared to moderate asthma. Chest 2008; 133:420-6.
77. Benayoun L, Druilhe A, Dombret MC, Aubier M, Pretolani M. Airway structural alterations selectively associated with severe asthma. Am J Respir Crit Care Med 2003; 167:1360-8.
78. Macedo P, Hew M, Torrego A et al. Inflammatory biomarkers in airways of patients with severe asthma compared with non-severe asthma. Clin Exp Allergy 2009; 39:1668-76.
79. Kaminska M, Foley S, Maghni K et al. Airway remodeling in subjects with severe asthma with or without chronic persistent airflow obstruction. J Allergy Clin Immunol 2009; 12:45-51.
80. Tillie-Leblond I, de Blic J, Jaubert F, Wallaert B, Scheinmann P, Gosset P. Airway remodeling is correlated with obstruction in children with severe asthma. Allergy 2008; 63:533-41.
81. Johnson PR, Roth M, Tamm M et al. Airway smooth muscle cell proliferation is increased in asthma. Am J Respir Crit Care Med 2001; 164:474-7.
82. Kaur D, Saunders R, Berger P et al. Airway smooth muscle and mast cell-derived CC chemokine ligand 19 mediate airway smooth muscle migration in asthma. Am J Respir Crit Care Med 2006; 174:1179-88.
83. Brightling CE, Bradding P, Symon FA, Holgate ST, Wardlaw AJ, Pavord ID. Mast cell infiltration of airway smooth muscle in asthma. N Engl J Med 2002; 346:1699-705.
84. Brightling CE, Symon FA, Holgate ST, Wardlaw AJ, Pavord ID, Bradding P. Interleukin-4 and -13 expression is co-localised to mast cells within the airway smooth muscle in asthma. Clin Exp Allergy 2003; 33:1711-6.
85. Siddiqui S, Mistry V, Doe C et al. Airway hyperresponsiveness is dissociated from airway wall structural remodelling. J Allergy Clin Immunol 2008; 122:335-41.
86. Saunders R, Siddiqui S, Kaur D et al. Fibrocyte localisation to the airway smooth muscle is a feature of asthma. J Allergy Clin Immunol 2009; 123:376-84.
87. Wang CH, Huang CD, Lin HC et al. Increased circulating fibrocytes in asthma with chronic airflow obstruction. Am J Respir Crit Care 2008; 178:583-91.
88. Siddiqui S, Hollins F, Brightling CE. What can we learn about airway smooth muscle from the company it keeps? Eur Respir J 2008; 32:9-11.
89. Siddiqui S, Sutcliffe A, Shikotra A et al. Vascular remodelling is a feature of asthma and nonasthmatic eosinophilic bronchitis. J Allergy Clin Immunol 2007;120:813-9.
90. Simcock DE, Kanabar V, Clarke GW, O'Connor BJ, Lee TH, Hirst SJ. Proangiogenic activity in bronchoalveolar lavage fluid from patients with asthma. Am J Respir Crit Care Med 2007; 176:146-53.
91. Zannini A, Chetta A, Saetta M et al. Chymase-positive mast cells play a role in the vascular component of airway remodelling in asthma. J Allergy Clin Immunol 2007; 120:329-33.
92. Carroll NG, Mutavdzic S, James AL. Increased mast cells and neutrophils insubmucosal mucous glands and mucus plugging in patients with asthma. Thorax 2002; 57:677-82.
93. Carroll N, Carello S, Cooke C, James A. Airway structure and inflammatory cells in fatal attacks of asthma. Eur Respir J 1996; 9:709-15.
94. Brightling CE, Desai D, Siddiqui S. Severe asthma: a consequence of over exuberant repair? Clin Exp Allergy 2009; 39:1630-2.
95. Macedo P, Hew M, Torrego A et al. Inflammatory biomarkers in airways of patients with severe asthma compared to non-severe asthma. Clin Exp Allergy 2009; 39:1668-76.
96. Kaminski M, Foley S, Maghni K et al. Airway remodelling in subjects with severe asthma with or without chronic persistent airflow obstruction. J Allergy Clin Immunol 2009; 124:45-51.
97. Bourdin A, Neveu D, Vachier I, Paganin F, Godard P, Chanez P. Specificity of basement membrane thickening in severe asthma. J Allergy Clin Immunol 2007; 119:1367-74.
98. Chakir J, Shannon J, Molet S et al. Airway remodeling-associated mediators in moderate to severe asthma: effect of steroids on TGF-beta, IL-11, IL-17, and type I and type III collagen expression. J Allergy Clin Immunol 2003; 111:1293-8.
99. Ueda T, Niimi A, Matsumoto H et al. Role of small airways in asthma: investigation using high-resolution computed tomography. J Allergy Clin Immunol 2006; 118:1019-25.
100. Sorkness RL, Bleecker ER, Busse WW et al. ; National Heart, Lung, and Blood Institute Severe Asthma Research Program. Lung function in adults with stable but severe asthma: air trapping and incomplete reversal of obstruction with bronchodilation. J Appl Physiol 2008;104:394-403.
101. Dolhnikoff M, da Silva LF, de Araujo BB et al. The outer wall of small airways is a major site of remodeling in fatal asthma. J Allergy Clin Immunol 2009;123:1090-71097.e1
102. Mauad T, Silva LF, Santos MA et al. Abnormal alveolar attachments with decreased elastic fiber content in distal lung in fatal asthma. Am J Respir Crit Care Med 2004; 170:857-62.
103. Mauad T, Xavier AC, Saldiva PH, Dolhnikoff M. Elastosis and fragmentation of fibres of the elastic system in fatal asthma. Am J Respir Crit Care Med 1999; 160:968-75.
104. Matsushita MM, Silva LFF, Santos MA et al. Airway proteoglycans are differentially altered in fatal asthma. J Pathol 2005; 207:102-10.
105. Pini L, Hamid Q, Shannon J et al. Differences in proteoglycan depostion in the airways of moderate and severe asthmatics. Eur Respir J 2007; 29:71-7.
106. De Kluijver J, Schrumpf JA, Evertse CE et al. Bronchial matrix and inflammation respond to inhaled steroids despite ongoing allergen exposure in asthma. Clin Exp Allergy 2005; 35:1361-9.
107. Bergeron C, Hauber HP, Gotfried M et al. Evidence of remodelling in peripheral airways of patients with mild to moderate asthma: effects of hydrofluoroalkane-flunisolide. J Allergy Clin Immunol 2005; 116:983-9.
108. Pepe C, Foley S, Shannon J et al. Differences in airway remodeling between subjects with severe and moderate asthma. J Allergy Clin Immunol 2005; 116:544-9.
109. van Rensen EL, Sont JK, Evertse CE et al. Bronchial CD8 cell infiltrate and lung function decline in asthma. Am J Respir Crit Care Med 2005; 172:837-41.
110. Jeffery PK, Wardlaw AJ, Nelson FC, Collins JV, Kay AB. Bronchial biopsies in asthma. An ultrastructural, quantitative study and correlation with hyperreactivity. Am Rev Respir Dis 1989; 140:1745-53.
111. Ohashi Y, Motojima S, Fukuda T, Makino S. Airway hyperresponsiveness, increased intracellular spaces of bronchial epithelium, and increased infiltration of eosinophils and lymphocytes in bronchial mucosa in asthma. Am Rev Respir Dis 1992; 145:1469-76.
112. Lozewicz S, Wells C, Gomez E et al. Morphological integrity of the bronchial epithelium in mild asthma. Thorax 1990; 45:12-5.
113. Hoshino M, Nakamura Y, Hamid QA. Gene expression of vascular endothelial growth factor and its receptors and angiogenesis in bronchial asthma. J Allergy Clin Immunol 2001; 107:1034-8.
114. Woodruff PG, Dolganov GM, Ferrando RE et al. Hyperplasia of smooth muscle in mild to moderate asthma without changes in cell size or gene expression. Am J Respir Crit Care Med 2004; 169:1001-6.
115. Levy BD, Bonnans C, Silverman ES, Palmer LJ, Marigowda G, Israel E. Diminished lipoxin biosynthesis in severe asthma. Am J Respir Crit Care Med 2005; 172:824-30.
116. Vachier I, Bonnans C, Chavis C et al. Severe asthma is associated with a loss of LX4, an endogenous anti-inflammatory compound. J Allergy Clin Immunol 2005; 115:55-60.
117. Petasis NA, Akritopoulou-Zanze I, Fokin VV et al. Design, synthesis and bioactions of novel stable mimetics of lipoxins and aspirintriggered lipoxins. Prostaglandins Leukot Essent Fatty Acids 2005; 73:301-21.
118. Vercelli D. Discovering susceptability genes for asthma and allergy. Nat Rev Immunol 2008; 8:169-82.
119. Weiss ST. Lung function and airway diseases. Nat Genet 2010;42:14-6.
120. Van Eerdewegh P, Little RD, Dupuis J et al. Association of the ADAM33 gene with asthma and bronchial hyperresonsiveness. Nature 2002; 418:426-30.
121. Denham S, Koppelman GH, Blakey J et al. Meta-analysis of genome-wide linkage studies of asthma and related traits. Respir Res 2008; 9:38.
122. Moffatt MF, Kabesch M, Liang L et al. Genetic variants regulating ORMDL3 expression contribute to the risk of childhood asthma. Nature 2007; 448:470-3.
123. Ober C, Tan Z, Sun Y et al. Effect of variation in CH13L1 on serum YKL-40 level, risk of asthma, and lung function. N Eng J of Med 2008; 358:1682-91.
124. Himes BE, Hunninghake GM, Baurley JW et al. Genome-wide association analysis identifies PDE4D as an asthma-susceptability gene. Am J Hum Genet 2009; 84:581-93.
125. Li X, Howard TD, Zheng S, Meyers DA, Bleecker ER. Genome-wide association study of asthma identifies RAD50-IL13 and HLA-DR/DQ regions. J Allergy Clin Immunol 2010; 125:328-35.
126. Moffatt MF, Gut IG, Demenais F et al. GABRIEL Consortium. N Engl J Med 2010; 363:1211-21.
127. Wan YI, Soler-Artigas M, Shrine NRG et al. Genome-wide association study to identify genetic determinants of severe asthma (AUGOSA), American Thoracic Society Conference Proceedings 2011 (abstract). Available at:
128. Wenzel SE, Balzar S, Ampleford EJ et al. Il-4Rα Mutations are associated with asthma exacerbations, airway obstruction, tissue mast cells/IgE expression and racial background. Am J Resp Crit Care Med 2007; 175:570-6.
129. Ten Brinke A, Zwinderman AH, Sterk PJ, Rabe KF, Bel EH. Factors associated with persistent airflow limitation in severe asthma. Am J Respir Crit Care Med 2001; 164:744-8.
130. Moore WC, Meyers DA, Wenzel SE et al. National Heart, Lung, and Blood Institute's Severe Asthma Research Program. Identification of asthma phenotypes using cluster analysis in the Severe Asthma research Program. Am J Respir Crit Care Med 2010; 181:315-23.
131. Green RH, Brightling CE, McKenna S et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360:1715-21.
132. Leckie MJ, Ten Brinke A, Khan J et al.Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000; 356:2144-8.
133. Nair P, Pizzichini MMM, Kjarsgaard M et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009; 360:985.
134. Burrowes KS, Swan AJ, Warren NJ, Tawhai MH Towards a virtual lung: multi-scale, multi-physics modelling of the pulmonary system. Philos Transact A Math Phys Eng Sci 2008; 366:3247-63.
135. Brook BS, Peel SE, Hall IP et al. A biomechanical model of agonist-initiated contraction in the asthmatic airway. Respir Physiol Neurobiol 2010; 170:44-58.
136. Available at (accessed 30 November 2011)
137. Auffray C, Chen Z, Hood L. Systems medicine: the future of medical genomics and healthcare. Genome Med 2009; 1:2.
138. Pavord ID, Cox G, Thomson NC et al. RISA Trial Study Group. Safety and efficacy of bronchial thermoplasty in symptomatic severe asthma. Am J Respir Crit Care Med 2007; 176:1185-91.
139. Castro M, Rubin AS, Laviolette M et al. AIR2 Trial Study Group. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomised, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med 2010; 181:116-24.
140. Cox G, Thomson NC, Rubin AS et al. ; AIR Trial Study Group. Asthma control during the year after bronchial thermoplasty. N Engl J Med 2007; 356:1327-37.
141. Corren J, Lemanske RF, Hanania NA et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011; 365:1088-98.